https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=BioAtla%2C_Inc.BioAtla, Inc. - Revizia istoricului2026-04-11T13:08:27ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=BioAtla,_Inc.&diff=408851&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei BioAtla, Inc. listata cu simbolul US.BCAB ==Descriere companie== BioAtla, Inc. (www.bioatla.com) is a clinical-stage biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. Its product candidate includes BA3011, BA3021, BA3071. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL. its second product ca...2024-09-18T13:41:29Z<p>Pagină nouă: Pagina dedicata companiei BioAtla, Inc. listata cu simbolul US.BCAB ==Descriere companie== BioAtla, Inc. (www.bioatla.com) is a clinical-stage biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. Its product candidate includes BA3011, BA3021, BA3071. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL. its second product ca...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei BioAtla, Inc. listata cu simbolul US.BCAB<br />
<br />
==Descriere companie==<br />
BioAtla, Inc. (www.bioatla.com) is a clinical-stage biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. Its product candidate includes BA3011, BA3021, BA3071. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL. its second product candidate, BA3021, which is a CAB ADC targeting ROR2. Its third product candidate, BA3071, is a CAB anti-CTLA-4 antibody. The Company also uses its CAB technology to develop bispecific antibodies, which bind both a tumor-specific antigen and a T cell receptor using CAB antigen-binding domains. Its bispecific product candidate includes BA3182, BA3142, EGFR and Nectin-4.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.BCAB" /><br />
<br />
==Ultimele stiri despre BioAtla, Inc. (US.BCAB)==<br />
<dynamicpagelist><br />
category=US.BCAB<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.BCAB]][[Categorie:Stiri despre companii]]</div>Admin